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h THIS PAPER CONCERNS the modeling of the effect
of intravenous anesthetics in the human body and is
justified by the potential that individualized modeling
has in the design of feedback controllers for drug
delivery in clinical anesthesia. These controllers are
part of a cyber–physical system (CPS) for closed-loop
drug delivery in anesthesia; see Figure 1. The
phenomenon (plant) to be controlled is the effect
(output) of the drugs (inputs) in the human body. The
controller in Figure 1a can be implemented in a
personal computer, as in Figure 1b. The syringe pumps
(actuators) are as shown on the left in Figure 1b and
the monitors that collect the measurements from the
sensors placed on the pa-
tient are shown at the top of
Figure 1b.
D e s p i t e t h e g r e a t
achievements of the last
years, the potential of
closed-loop controllers in
the daily clinical practice is
still poorly exploited. In an-
esthesia, even though several
attempts have been made to
completely automate the
drug delivery to patients, no technique has become
widely accepted. The mismatch between research and
practice is mainly due to legal regulations. In fact, the
chances of approval of any closed-loop control strategy
by the regulatory entities are likely to increase with
demonstration of a clinically significant safety benefit.
Those benefits may encompass a reduction of the
incidence of underdose- and overdose-induced com-
plications, as compared to standard clinical practice.
One of the crucial aspects that affects the ade-
quacy of the drug administration protocol to each
patient, and consequently might determine the pre-
sence of the unwanted underdosing and overdosing,
is the knowledge that the anesthesiologist has of the
patient’s individual response to the drug. In an auto-
matic system, suitable models to describe the pro-
cesses involved have to be formulated. On the one
hand, if the purpose of the modeling is to obtain
deep insight in the physiology behind the process,
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first principles models are usually preferred. On the
other hand, in case the purpose is either prediction
of the behavior of the system or model-based con-
trol, low-complexity models whose parameters are
inferred from experimental data [18] are often more
suitable. The modeling choice is specially important
in environments that are not data-rich, or where the
inputs are not allowed to be arbitrarily selected to
optimize the result of identification. This is precisely
the case in general anesthesia, where the adminis-
tered drug doses have to comply with the intervals
determined by the regulatory entities.
Furthermore, the model chosen to characterize
the dynamical effect of the administered drugs on
the measured physiological variables should be
able to reflect variations from
patient to patient, known as
interpatient variability. Themod-
el should also reflect variability
within the same patient under
different conditions, e.g., varia-
tions in cardiac output, and/or
coadministered drugs, known
as intrapatient variability. This
implies that the models chosen
should be accurate representa-
tions of the system dynamics,
being at the same time flexible
enough to allow adaptation to
each individual patient.
The contribution of this pa-
per is to provide an overview of
some of the models that are
available in the literature for the
effect of anesthetics in the hu-
man body. While first principles
models have been available for
30 years (see, e.g., [5]), their use
in individualized drug adminis-
tration is limited. This is mainly
due to the poor excitation pro-
vided by the input signals (drug
doses) that does not always al-
low unique estimation of the
model parameters. As a result,
the standard first principles mod-
els for the effect of anesthetics
appear to be somewhat overpar-
ameterized with respect to the
available experimental data [15].
This compromises the result of system identification
and effectively prevents individualized control. The
discussion of model choices in this paper has model-
based feedback control as end-goal, implemented as
a CPS. The potential of individualization that reduced
models provide via parameter estimation constitutes a
crucial benefit in the field of automated drug delivery
for anesthesia.
The remainder of this paper is organized in three
blocks. First, the first principles models used in
anesthesia are described. Second, the population
models using covariates to obtain values for themodel
parameters are summarized. Then, recent advances in
individualized modeling of anesthesia are presented.
Parsimonious models suitable for online parameter
Figure 1. Cyber–physical system for drug delivery in anesthesia.
(a) Schematic view of the feedback control scheme. The role of
the anesthesiologist is that of a supervisor. The dashed lines depict
indirect actions. The solid lines depict direct actions. The entities
depicted by the arrows can be vector-valued. (b) Overview of the
components of the CPS platform Galeno [17].
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estimation and system identification methods devel-
oped for model-based individualized control are
outlined. Finally, conclusions are provided.
First principles models
First principles models for the effect of anesthe-
tics were developed based on the knowledge of the
physiology of the system and using collected blood
samples at different instants after the anesthetics are
administered to patients. The path from the admin-
istered amount of drug to the measured effect is
hence divided into two parts. First, the pharmacoki-
netics (PK) describes ‘‘what the body does to the
drug’’ and concerns the drug distribution and meta-
bolism in the blood stream. The input to the PK block
is the amount of drug administered and the output is
the drug blood plasma concentration. Second, the
pharmacodynamics (PD) describes ‘‘what the drug
does to the body.’’ The input to the PD block is the
blood plasma concentration and the output is the
physiological variable that quantifies the effect of
the drug. In this context, the joint effect of hypnotics
and analgesics is denoted by depth of anesthesia
(DoA), while the effect of muscle relaxants is
denoted by neuromuscular blockade (NMB).
Supported by the experimental evidence, it is
natural to model the effect of drugs in anesthesia by
two cascaded blocks. Due to the fact that the majo-
rity of the PK of the drugs can be captured by linear
time-invariant (LTI) dynamics, and the PD includes a
static nonlinearity, a Wiener model (Figure 2) has
become a popular choice.
The distribution of the drugs in the body depends
on several transport and metabolic processes. Com-
partmental models [5] capture this behavior by
considering the body divided in physiologically mo-
tivated compartments that exchange (positive)
amounts of drugs between themselves. Conservation
laws that assume that the total amount of drug in the
system (i.e., the body including the cleared/excreted
drug amount) remains constant throughout the du-
ration of the surgery are used to derive the associated
dynamics. Two or three compartmental models [5]
are the ones most commonly used to describe the LTI
PK of muscle relaxants, hypnotics, and analgesics.
For the case of both propofol and remifentanil, a
three-compartmental model is commonly used [10],
assuming that, for each compartment i; i ¼ 1; 3 at
time t, a concentration ciðtÞ ¼ xiðtÞ=Vi [mg ml$ 1] of
drug is present. Here Vi denotes the volume of com-
partment i, and xi is the amount of drug in the same
compartment. In clinical practice, the amounts of
drugs in each compartment cannot be measured
online. In an offline model fitting framework, it is
only possible to obtain readings of the drug concen-
trations in the blood, i.e., in compartment 1. Assum-
ing that uðtÞ [mg ml$ 1 min$ 1] is the drug infusion
rate (either propofol or remifentanil), k10 [min$ 1] is
the clearance (rate) of the drug from compartment 1,
ke0 [min$ 1] is the clearance of the drug from the
effect compartment, kij [min$ 1] are transfer coeffi-
cients from compartment i to compartment j, and
ceðtÞ [mgml$ 1] is the effect concentration of the drug,
a state–space representation of the linear dynamic
distribution of each drug in the different theoretical
compartments of the human body becomes
xðtÞ ¼AxðtÞ þ BuðtÞ (1a)
ceðtÞ ¼CxðtÞ (1b)
A ¼
$ ðk10 þ k12 þ k13Þ k21 k31 0
k12 $ k21 0 0
k13 0 $ k31 0
ke0 0 0 $ ke0
26664
37775
(1c)
B ¼ ½ 1 0 0 0 'T (1d)
C ¼ ½ 0 0 0 1 ': (1e)
Model (1) accounts for the fact that blood is not
the effect site of any of the intravenous anesthetics
mentioned above, by connecting an additional
virtual effect compartment to the central compart-
ment. In order to ensure that the equilibrium of the
PK is not affected, it is assumed that this virtual
compartment has negligible volume. This constitu-
tes the linear part of the PD model, modeled by the
last row in (1c).
Figure 2. Wiener model: a linear
time-invariant (LTI) dynamics cascaded
with a static nonlinearity. The input u
is the administered anesthetic, ce is a
nonmeasurable variable, and the output y is
themeasuredeffect. Ingeneral, thequantities
depicted by arrows can be vector valued.
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At the effect site, the way anesthetics act has a
more involved characterization than their distribu-
tion in the body. Empirical models are therefore used
to describe this part of the PD. The classic and most
commonly used description is the Hill function, a
sigmoid static nonlinear function relating the effect
concentration of the drug with its observed effect.
For the single-input–single-output (SISO) model, as
for the NMB case, the static nonlinear Hill function
[11] can be expressed as
yðtÞ ¼ y0 þ ðymax $ y0Þ c
!
e ðtÞ
C!50 þ c!e ðtÞ
(2)
where y0 is the baseline effect when no drug is pre-
sent, ymax is the value of the output at the maximum
drug effect, C50 is the concentration associated with
the 50% drug effect, and ! is a ‘‘sigmoidicity factor’’
that determines the steepness of the curve. This
relation is shown graphically in Figure 3a for the SISO
case with y0 > ymax.
For the multiple-input–single-output (MISO) case
of two interacting drugs A and B, the potency of the
drug mixture can be modeled as [11]
"ðtÞ ¼ UBðtÞ
UBðtÞ þ UAðtÞ (3)
where, by definition, "ðtÞ ranges from 0 (drug A
only) to 1 (drug B only).
To calculate (3), both effect concentrations ceAðtÞ
and ceBðtÞ are first normalized with respect to their
concentration at half the maximal effect (C50A and
C50B, respectively) as
UAðtÞ ¼ ce;AðtÞC50A UBðtÞ ¼
ce;BðtÞ
C50B
: (4)
The nonlinear concentration–response relationship
for any ratio of the two drugs can then be described
by the generalized Hill function
yðtÞ ¼ y0 þ ðymax $ y0Þ
UAðtÞþUBðtÞ
U50 "ðtÞð Þ
! "!
1þ UAðtÞþUBðtÞU50 "ðtÞð Þ
! "! (5)
where y0, ymax, and ! are as defined before, and
U50ð"ðtÞÞ is the number of units associated with 50%
of the maximum effect of both drugs at ratio "ðtÞ.
This relation is shown graphically in Figure 3b for
the MISO case with y0 > ymax.
In [11], the quadratic polynomial
U50 "ðtÞð Þ ¼ 1 $ #"ðtÞ þ #"2ðtÞ (6)
with # > 0 was proposed for the expression of
U50ð"ðtÞÞ for the case of the synergistic interaction
between propofol and remifentanil.
Because the majority of the indices used to mea-
sure the effect of propofol and remifentanil are
bounded from below by zero, ymax ¼ 0 should be
considered. For instance, the patient-dependent pa-
rameters in the propofol–remifentanil-induced DoA
standard model are hence the following seventeen:
k10p; k12p; k13p; k21p; k31p; ke0p, for propofol, k10r; k12r;
k13r; k21r; k31r; ke0r, for remifentanil, and C50p, C50r, !,
#, and y0.
Population models
The question on whether the PK parameters in
(1) for propofol and remifentanil correlate with, e.g.,
age, sex, and height of the patients arose after the
pioneering trials of automatizing the drug delivery to
patients under anesthesia. The method to obtain
population models relies on regressions made on
collected blood samples from patients at different
instants after administration of anesthetics. A com-
mon method is as described in [7]. In the first step,
individual estimates of the PK/PD parameters are
obtained as empirical Bayesian estimates, based on
a prior using no covariates. In the second step, the
individual PK/PD parameter estimates are regressed
Figure 3. Static nonlinear Hill function for:
(a) SISO case and (b) MISO case. The y’s
denote the outputs and the ce’s denote
the inputs to the nonlinearity.
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on the covariates using a generalized additive model.
In the third and final step, the software NONMEM is
used to optimize the population model [7]. This ap-
proachwas used in, e.g., [10] for theMinto population
model of remifentanil.
When it comes to propofol models for adults, the
Marsh model and the Schnider model [14] are the
most well known and used in the clinical practice,
particularly in the so-called target controlled infusion
(TCI) devices; see, e.g., [1]. The TCI devices imple-
ment open-loop control approaches to drug delivery.
The anesthesiologist, based on the status of the patient
and on the progress of the anesthetic procedure, sets
the target concentration (setpoint) and the TCI device
calculates the corresponding drug profile to be
administered by inverting the linear part (1) of the
PK/PDmodel. The target can be either set at the blood
or the effect concentration. The parameters kij in (1)
are estimated based on population model distribu-
tions, using the relationships in, e.g., [14] for the case
of propofol, or in [11] for the case of remifentanil.
The predictive performance of the aforemen-
tioned models for a population of adults was as-
sessed in several studies; see, e.g., [1, Table 4] for a
summary. An average population underprediction of
20% in the blood concentration of propofol using the
Marsh model and an average overprediction of the
measured remifentanil concentration by 15%, with
an average inaccuracy of 20% were found. It should
be noted that, even though being capable of explain-
ing the variability of responses in a population, these
models are not tailored to capture each individual
response to the anesthetics, and may give higher
inaccuracies when used in an individualized model-
based control framework.
Regarding the nonlinear PD, the work in [9] pro-
poses a population distribution for the parameters !,
#, and C50 in nonlinear interaction (4)–(6). Again,
these parameters are not individualized, but rather
population based and, to the authors’ knowledge, no
study with covariate regression has been published
for the case of the propofol and remifentanil PD. In
common clinical practice in using TCI, these non-
linear interaction parameters are usually inferred
from the signs that are collected from the patient,
and based on the clinicians’ expertise.
Individualized models
Before the beginning of a general anesthesia pro-
cedure, the only information that is available about
the patient are his/her weight, height, sex, and clini-
cal history. Even though providing guidelines, none
of these, unfortunately, gives an accurate picture of
how the patient will react once the intravenous anes-
thetics are administered. However, with the progress
of the surgery, more andmore data become available
to characterize each patient’s individual response to
the administereddrug. It is then natural to conjecture
that methods that learn the response of the patient to
the administered drug online can provide valuable
information to characterize the individual response
to the anesthetics. This is the idea behind recursive
system identification [18].
As shown in [15], the standard PK/PD models
described in Section II seem to be overparameter-
ized for the case of NMB and DoA, considering the
input signals (drug doses) commonly administered
in the clinical practice. On the one hand, the bolus
dose (that may be seen as a pulse of a finite ampli-
tude) that is administered in open loop during the
induction phase yields rich information on the non-
linearity. On the other hand, the information col-
lected during closed-loop operation is limited to a
certain point of nonlinearity, corresponding to the
setpoint. Naturally, more information about the dyna-
mics of the system may be collected instead, but the
closed-loop feedback signal is poorly excitatory. This
is particularly troublesome because the input signals
are subject to the clinical protocols and cannot be
freely chosen to facilitate a better performance of the
system identification methods.
The work in, e.g., [16] proposes minimally param-
eterized Wiener models for the effect of intravenous
anesthetics. Themodels keep theWiener structure of
the PK/PD ones and were developed using real data.
The two main observations that motivated the de-
velopment of these models were as follows.
First, the linear dynamics of the standard models
are, considering the data available, ‘‘practically’’
overparameterized. The sensitivity and identifiability
work in [15] provided insights on which parameters
are poorly identifiable given the typical administered
drug doses. Further, in some cases, the linear part of
the model exhibits nearly pole-zero cancellation,
which indicates a need for model reduction while
keeping the same cascade structure of the model.
The fact that the Wiener model structure is retained
still allows for some physical connection to the stan-
dard PK/PD models and facilitates, e.g., the interpre-
tation of the system identification results.
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Second, the Wiener structure provides the system
with enough nonlinear behavior, while enabling,
e.g., inversion of the nonlinearity. It is therefore rela-
tively simple to use for both identification and indi-
vidualized closed-loop control.
The minimally parameterized model for the
propofol–remifentanil DoA is shown here to ex-
emplify the modeling idea. In [16], a third-order
continuous-time model was proposed for the linear
dynamics of both propofol and remifentanil. The
transfer function of the linear dynamic part of the
Wiener model for propofol is given by
GpðsÞ ¼ $sþ $
d1$
sþ d1$
d2$
sþ d2$ (7)
that may be realized in a state–space form as
xðtÞ ¼AxðtÞ þ BuðtÞ (8a)
ceðtÞ ¼CxðtÞ (8b)
A ¼
$ d2$ 0 0
d1$ $ d1$ 0
0 $ $ $
264
375 (8c)
B ¼ ½ d2$ 0 0 'T (8d)
C ¼ ½ 0 0 1 ': (8e)
The parameters di ; i ¼ 1; 2; are determined off-
line using previously collected real data and are
chosen to be constant and equal to 9 and 10,
respectively [16]. The individualization parameter
to be estimated online is $ > 0.
The state–space model equivalent to (8) for the
case of the NMB was shown to be a compartmental
model [5]. This is an important feature of a model
for drug delivery because it allows, e.g., the develop-
ment of compartmental control laws, as in, e.g., [17].
The transfer function of the linear dynamic part
of the Wiener model for remifentanil is similarly
given by
GrðsÞ ¼ %sþ %
l1%
sþ l1%
l2%
sþ l2% : (9)
The parameters li , i ¼ f1; 2g, are determined
offline from historical data and are chosen to be
equal to 2 and 3, respectively [16]. The individual-
ization parameter to be estimated online is % > 0.
The transfer function given by (9) may be realized in
state–space form similarly to (8).
Using the standard model in (5) as a starting
point, and considering ymax ¼ 0 for the case of most
of the DoA indices, a new formulation for the MISO
nonlinearity (5) was proposed in [16] as
yðtÞ ¼ y0
1þ yrðtÞC50r þm
cepðtÞ
C50p
! "& (10)
wherem and & are individualization parameters and
y0 is set depending on the monitoring device in use,
and C50p and C50r are propofol and remifentanil
normalizing constants, respectively [16], that are
fixed and nonpatient dependent.
From this, the patient-dependent parameters in the
DoA minimally parameterized model are hence the
following four: $, %,m, and &. Due to this low number
of parameters, efficient recursive parameter estima-
tion methods could be developed, as in, e.g., [16].
With the online parameter estimation, the accuracy of
the obtained models for each individual is better than
when population models were used; see, e.g., [8].
Online parameter estimation
The sensitivity and local identifiability analysis in
[15] revealed useful information on the potential of
both the first principles models and the minimally
parameterized models in providing reliable pa-
rameter estimates for closed-loop controller design.
Results show that, e.g., for the case of the first prin-
ciples model for the propofol–remifentanil DoA, five
parameters from the LTI blocks (1) and C50r and &
from the nonlinearity (2) may not be identifiable,
given the input excitation that is commonly present
in the clinical practice. On the other hand, the results
in Figure 4 show that the output is highly sensitive
to the parameters $, %, m, and &. Singular value
Figure 4. Output sensitivity function with respect to the
model parameters for the propofol–remifentanil DoA
minimally parameterized model (adapted from [15]).
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decomposition of the sensitivity matrix (see
[15, Table 7, App. B]) confirms the choices of $, %,
m, and & as the parameters to be estimated in the
minimally parameterized model.
Also, the results of [8] can be used to illustrate
the difference in predictive performance of the first
principles models and the minimally parameterized
models for the DoA. In Figure 5, it is clear that the
prediction using the minimally parameterized mod-
el outperforms the prediction using the first princi-
ples models. Both the initial transient and the global
trend of the signal are better captured by the blue
solid line, meaning that the individualization via
parameter estimation is likely to be more accurate if
the minimally parameterized models are used in the
estimation algorithms.
The minimally parameterized model was also
used for the development of adaptive model-based
controllers; see, e.g., [17]. The control scheme was
made adaptive by the use of the online parameter
estimates provided by an extended Kalman filter
(EKF). The reference tracking results are promising
and encourage the continuing use of the proposed
controller in the clinical practice.
In spite of the good results in closed loop ob-
tained with the EKF, owing to the nonlinear nature of
the system, it is expected that estimation algorithms
making direct use of the nonlinear model perform
better than estimation methods that rely on lineari-
zation. In [13], the minimally parameterized Wiener
model for the NMB was therefore estimated with a
particle filter (PF) and the estimation accuracy was
compared with that obtained by the EKF. It was
shown that the PF outperforms the EKF when it
comes to convergence rate, bias, and tracking capa-
bility. Using the parameter estimates obtained by the
PF, the intrapatient variability of the model is quan-
tified. The results strongly indicate that the variability
in the nonlinear PD part of the model is higher than
that of the linear part. Note that the computational
complexity of the PF is higher than that of the EKF.
This, however, is not an issue in this application since
the sampling rates of the signals are limited by the
monitoring devices, e.g., 1/20 s for the case of the
NMB or 1/5 s for the case of the DoA.
The performance of an individualized feedback
controller is, in fact, directly influenced by the intra-
patient variability. The presence of a high intrapatient
variability in the estimated models further supports
the use of the minimally parameterized models for
estimation toward individualized drug delivery in
anesthesia.
Some successful clinical cases of closed-loop
drug delivery with individualized estimation of the
parameters of the minimally parameterized model
can be found in, e.g., [17]. As shown in the upper
plot of Figure 6a, the NMB of a patient was controlled
to the setpoint via the administration of the drug rate
in the bottom plot in Figure 6a. The estimates of the
model parameters are shown in Figure 6b. For the
SISO NMB case, consider m ¼ 0 in (10).
While the linear design of controllers operating
around the almost linear region of the Hill function
could sometimes be sufficient, it would most likely
not guarantee performance under changes in the
patient’s dynamics. Also, the question on whether
nonlinear phenomena such as sustained oscillations
may appear due to the introduction of a controller in
the loop needs to be considered [21]. The research
in [21] is supported by the clinical evidence of oscil-
latory behavior in the literature for cases of closed-
loop drug delivery in anesthesia. The results of [21]
provide mathematical support to the clinical find-
ings. The bifurcation analysis in [21] shows that, for
the case of proportional–integral–derivative (PID)-
controlled NMB, complex nonlinear behavior such
as sustained oscillations may indeed appear under
certain conditions, as a consequence of Andronov–
Hopf bifurcation phenomena. These oscillations
result in underdosing and overdosing of anesthetics,
and should therefore be avoided. An expression for
Figure 5. Batch identification results for
case number 16 in the database in [8]:
the measured BIS is in pink dashed line;
the predicted BIS using the minimally
parameterized model is in blue solid line;
the predicted BIS using the first principles
model is in green solid line (results from [8]).
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the distance to such bifurcation is also suggested in
[21], giving rise to a way of monitoring how far the
closed-loop system is from sustained nonlinear
oscillations and thus quantifying the risk of the latter
events. Even though a PID controller designed based
on an individualized Wiener model [21] can initially
ensure a safe distance to bifurcation, the model
parameters sometimes drift close to a critical zone as
the surgery proceeds. The latter has been demon-
strated on clinical data in [13] by estimating the dis-
tance to the Andronov–Hopf bifurcation bymeans of
parameter estimation with a PF.
Provided that estimation of the model parameters
is performed, the PID tuning scheme in [22] ensures
that the closed-loop operating point of the drug de-
livery system is moved away from the region of oscil-
latory dynamics by changing the controller gains in a
systematic way. The proposed tuning allows the
closed-loop system to recover from oscillations that
were previously observed in clinical trials and that
led to underdosing and overdosing of the adminis-
tered drug. By introducing a time-varying propor-
tional PID gain, the type of equilibrium remains the
same as in the case of constant controller gains. This
is desirable since no additional complex nonlinear
behavior is introduced by this tuning [22].
Other models with reduced complexity
Several other papers advocating low complexity
modeling for the effect of intravenous drugs in anes-
thesia have also appeared in the literature recently.
For the case of the NMB, the idea of using a simple
modelwas exploited in, e.g., [2]. In [2], a logarithmic
transformation was applied to the model output
and, based on real data, a linear relationship be-
tween the effect concentration of the muscle relax-
ant atracurium and the transformed output variable
was suggested.
In [6], a simplified linear MISO interaction model
for the effect of propofol and remifentanil in the bi-
spectral index (BIS) is proposed. The reasoning be-
hind this simplification is that, in the intensive care
unit (ICU), the BIS levels are inside a 40–60 window,
which is the region where the interaction surface
described by (5) is assumed to reduce to a plane [6].
The use of this linear model in a model-based con-
troller should however be performed with some
caution during, e.g., the induction phase, where the
BIS signals typically decrease from a value close to
100 to 30. Additional safety nets should be consid-
ered in that case. The time delay in the linear MISO
relationship in [6] is estimated online by a method
proposed by the same authors. The first-order plus
time-delay (FOPTD) block of the FOPTD–Hill model
in [19] also considers an explicit delay that is iden-
tified after the initial 8 min of the induction phase.
Nevertheless, the minimal output error-norm repre-
sentation in [19] shows that, for the considered data,
the model is unidentifiable along a path in the time-
delay/Hill parameter space representation.
More recently, a reduced model for the hypnosis–
remifentanil-induced DoAwith only four parameters
Figure 6. Real closed-loop control results using the
minimally parameterized model for individualization
of drug delivery administration for the NMB (adapted
from [17]). (a) Upper plot: controlled NMB y and
reference y(. Bottom plot: control input (rocuronium
infusion rate). (b) Upper plot: estimates of parameter %.
Bottom plot: estimates of parameter &.
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was proposed in [20] and its performance com-
pared with other complex model structures.
The number of models with low complexity and
the successful closed-loop control strategies using
these models that can now be found in the literature
are strong indicators that model reduction is a
correct path toward individualization of drug deliv-
ery to patients under anesthesia.
CPS for drug delivery
As mentioned at the beginning of this paper, the
introduction of a CPS for drug delivery in daily clini-
cal anesthesia has to be preceded by rigorous test-
ing procedures to ensure its safe operation.
On the one hand, the predictive performance of
the models with a reduced number of parameters is
likely to be higher than that obtained with the stan-
dard overparameterized models. Therefore, outliers
and fault detections, aspects that are critical in
closed-loop, would also be more reliable and safer.
Monitoring functions to ensure that no nonlinear
phenomena like sustained oscillations arise in the
loop should also be part of the CPS.
On the other hand, the importance of reliable in-
terfaces is unquestionable. Related to this, anesthe-
sia control over wireless interfaces is a likely future
development. There aremany scenarios, e.g., natural
catastrophes, disasters, and war, when one could
benefit from such functionality. One may consider
situations when medical staff without detailed
knowledge of the field are forced to serve as anes-
thesiologists. A plausible solution would then be to
let the medical staff handle the actuator and the
sensor in the control loop discussed in this paper.
The controller and support functions could be re-
mote and connect with the local actuator/sensor
node over wireless interfaces. In that way, one central
control unit could serve perhaps hundreds of on-
going operations simultaneously. The actuator and
sensor could, e.g., be integrated in a dedicated
smartphone and the current cellular networks could
be employed to provide the wireless interface.
There are a number of issues that then would
need a further study. Wireless protocols for machine-
to-machine communication would need develop-
ment. These protocols would have to tailor, e.g., the
bit error probability of the transmission to levels
tolerable by the closed-loop anesthesia application.
The capacity and the area coverage of the service
would have to be optimized as well. Here it deserves
to bementioned that a reduced required closed-loop
bit rate would be beneficial for coverage, a fact that
can be understood by considering the possibility to
do repetition coding. It would probably be advisable
to consider the knowledge collected in the field of
networked control systems during the last 15 years;
see, e.g., [3], [4], and [12].
THIS PAPER PROVIDED an overview of the models
used for the effect of intravenous anesthetics, span-
ning from first principles models to low complexity
parsimonious ones that were recently proposed. The
lesson learned is that system identification models,
with reduced complexity, enable an accurate and
individualized characterization of the behavior of
the system, via online estimation of the model pa-
rameters. This capability is crucial and should be
used when the design of closed-loop controllers for
automated drug delivery to patients under anesthe-
sia is the end goal, implemented as a CPS. h
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